教員業績データベース |
|
論文種別 | 症例報告 |
言語種別 | 英語 |
査読の有無 | 査読あり |
表題 | Pazopanib treatment of a platinum-resistant recurrence of a high-grade Sertoli cell tumor and assessment of the treatment response by FDG-PET/CT: A case report. |
掲載誌名 | 正式名:Gynecologic oncology reports 略 称:Gynecol Oncol Rep ISSNコード:2352-5789(Print)2352-5789(Linking) |
掲載区分 | 国外 |
巻・号・頁 | 24,pp.54-56 |
著者・共著者 | Inoue Kayo, Tsubamoto Hiroshi, Ishida-Nisigami Keiko, Torii Yoshitaka, Hirota Seiichi |
発行年月 | 2018/05 |
概要 | Ovarian Sertoli cell tumors (SCTs) are rare sex cord tumors (Oliva et al., 2005). The standard treatment for high-grade SCTs is surgery followed by platinum-based chemotherapy. Although platinum-based chemotherapy is also an option for recurrent SCTs (Sigismondiet al., 2012), there is no established chemotherapy regimen for platinum-resistant recurrent SCTs. The effectiveness of pazopanib in treating epithelial ovarian cancer has recently been reported (du Bois et al., 2014; Pignata et al., 2015). In the case described herein, pazopanib was used to treat the platinum-resistant recurrence of a high-grade Sertoli cell tumor, and the response was evaluated by 18F-fluoro-deoxyglucose positron emission tomography (FDG-PET)-computed tomography (CT). Written informed consent to reporting the case was obtained from the patient. |
DOI | 10.1016/j.gore.2018.03.002 |
PMID | 29915800 |